Navigation Links
Quark Pharmaceuticals Announces Data Indicating Potential Utility of QPI-1007 for Treatment of Glaucoma
Date:7/27/2009

iRNAs and all of our pipeline candidates have exhibited optimal activity and stability while attenuating potential off-target effects."

Prof. Di Polo commented, "In patients with glaucoma, characteristic visual field changes and vision loss are caused by the death of retinal ganglion cells. While existing therapeutics are capable of reducing IOP, none act as selective neuroprotective agents. We are encouraged by the QPI-1007 data, which suggest a neuroprotective effect on retinal ganglion cells in experimental glaucoma, presenting a major breakthrough in novel treatments for this neurodegenerative disease."

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel RNAi-based therapeutics. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability for non-invasive delivery of siRNA to other target tissues including the eye, ear, lung, spinal cord and brain.

PF-4523655 (RTP801i-14), currently in Phase II clinical trials, is a synthetic, chemically modified siRNA designed to inhibit the expression of the gene RTP801 discovered by Quark through the gene discovery platform BiFAR. PF-4523655 is licensed to Pfizer. In addition, Quark's current clinical pipeline includes QPI-1002, the first systemically administered siRNA drug in human clinical trials, developed by Quark for the prevention of acute kidney injury (AKI) following major cardiovascular surgery and the prophylaxis of delayed graft function after kidney transplantation

Quark has a broad pipeline of siRNA drug candidates based on novel structures developed internally and is utilizing the chemistry
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Quark Pharmaceuticals Receives FDA Approval of IND for Kidney Transplant siRNA Drug DGFi
2. Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference
3. Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage
4. Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI-1002 in Chronic Kidney Disease at the RNA Interference Summit
5. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
10. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Aspen Advisors, a U.S.-based healthcare IT consulting firm, ... high morale and collaborative culture in the ... Work For 2014.” Consulting magazine publishes the popular ... participating across all major industries, representing more than 350 ... firms were ranked in six categories - firm culture, ...
(Date:9/16/2014)... and radiation therapy as part of breast conservation ... with hormone-receptor positive (HR+) invasive breast cancer. A ... Center, however, shows that combination may not be ... , The results, which Fox Chase researchers ... 56th Annual Meeting on Sunday, September 14, suggest ...
(Date:9/16/2014)... Seven heroes who have dramatically improved ... honored in New York City on November 6 by ... global recognition and funding program that honors individuals serving ... as the “Nobel Prize for Child Advocates,” this year’s ... that benefit children in countries around the world dealing ...
(Date:9/16/2014)... As part of its Latinos Living ... (LULAC) will host the second annual health festival in ... free health screenings for osteoporosis, HIV, and high blood ... cholesterol levels as well as bone marrow typing. In ... 6 years old , The event will also feature ...
(Date:9/16/2014)... HealthDay Reporter TUESDAY, ... U.S. cancer survivors are alive today, compared to just ... Research reported Tuesday. These individuals amount to 4 ... of childhood cancer, according to the association,s annual progress ... and treatment of cancer and details some of the ...
Breaking Medicine News(10 mins):Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 2Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 3Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 2Health News:Benefit of endocrine therapy in elderly women with low risk hormone receptor positive breast cancer? 3Health News:World of Children® Award Announces 2014 Honorees 2Health News:World of Children® Award Announces 2014 Honorees 3Health News:World of Children® Award Announces 2014 Honorees 4Health News:World of Children® Award Announces 2014 Honorees 5Health News:World of Children® Award Announces 2014 Honorees 6Health News:World of Children® Award Announces 2014 Honorees 7Health News:World of Children® Award Announces 2014 Honorees 8Health News:LULAC Hosts Second Annual Latinos Living Healthy Feria de Salud in Los Angeles 2Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 2Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 3Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 4
... that combines 2 medications , , SUNDAY, March 30 (HealthDay News) ... make sense of a trial showing that a drug can ... apparent benefit to people at high risk of heart attack ... well-known statin -- simvastatin -- with ezetimibe, which also lowers ...
... use with angioplasty following a heart attack, the anticoagulants ... measures within 90 minutes after the procedure, while patients ... a lower risk of major adverse cardiac events within ... to a JAMA study being released early online March ...
... risk and don,t increase mortality probability , , SUNDAY, March ... placed in diseased coronary arteries to keep them open, ... patients, new research shows. , In the largest study ... the drug in question retards the growth of arterial ...
... to Join Nation,s Largest RN ... Organization, ... registered nurses to have a stronger voice to speak,out for patients and ... to win union collective bargaining,rights., RNs at Cypress Fairbanks Medical Center ...
... deaths could be avoided with lifestyle changes, experts say, ... that could cut cancer deaths in half. , Well, ... American Cancer Society report that said as many as ... lifestyle changes, such as quitting smoking, maintaining a healthy ...
... mice was important protective mechanism, researchers say , , FRIDAY, March ... a critical role in protecting the heart during a heart ... It was already known that Gi increased activity in a ... helping the heart adapt to damage or if it actually ...
Cached Medicine News:Health News:Cholesterol Drug Controversy Continues 2Health News:Cholesterol Drug Controversy Continues 3Health News:Comparison of anticoagulants for angioplasty show similar outcomes 2Health News:Drug-Eluting Stents Safe After Heart Attack 2Health News:First Unionized Hospital in Texas 2Health News:First Unionized Hospital in Texas 3Health News:You May Be the Key to Cancer Prevention 2Health News:You May Be the Key to Cancer Prevention 3Health News:Key Protein Limits Damage of Heart Attack 2
(Date:9/16/2014)... , Sept. 16, 2014   Vestagen Technical Textiles, ... patient experience at hospitals. The myComfort™ line of patient ... barrier fabric that is fluid repellant, breathable and in ... the growth of bacteria on the fabric i . ... plays in the chain of transmission. We want myComfort ...
(Date:9/16/2014)... 2014 The Lupus Foundation of America and ... today released results from UNVEIL: understanding the impact of ... lupus journey and the challenges not only for those ... UNVEIL study, which involved over 1,000 people with lupus ... on all aspects of life including family, work, finances, ...
(Date:9/16/2014)... , Sept. 16, 2014 Imprimis Pharmaceuticals, Inc. ... dedicated to delivering high quality and novel medicines to ... Chief Executive Officer Mark Baum will be ... Alpha Select Conference in New York City.  Mr. Baum ... Go Dropless™ campaign in ophthalmology. The presentation is scheduled ...
Breaking Medicine Technology:New Vestagen Patient Garments Aim to Minimize Pathogen Transmission Inside Hospitals 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 2Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 3Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 4
The ring maintains the bag tension avoiding the development of posterior capsule pleats. It is also established to compensate the efforts induced during the bag retraction....
Mayo dissecting scissors with beveled blades....
Ribbon malleable, general purpose retractor....
The Wire Cutters are designed to cut Kirschner wires up to 2.5 mm diameter easily and smoothly. They are particularly useful for external fixation applications. The Wire Cutters shear fixation wires ...
Medicine Products: